Daniel Simon, MD
Vascular & Interventional Radiology · New Brunswick, NJNPI 1013997428
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.3%), other and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Angiodynamics, Inc. at 33.6% of the total. Reporting peaked in 2019 at $15,201 and has fallen 50.5% since, to $7,526 in 2025. Among vascular & interventional radiology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $187.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$14K
- Terumo Medical Corporation$14K
- Cordis US CORP.$5K
- Philips North America LLC$3K
- Siemens Medical Solutions USA, Inc.$2K
- Boston Scientific$1K
- plus $4K from 21 others
What the payments were for
- Consulting fees$19,07544%
- Speaking & faculty fees$2,0005%
- Travel & lodging$1,2103%
- Food & beverage$6,65715%
- Other$14,13033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 12 | $14,482 |
| Terumo Medical Corporation | 15 | $13,914 |
| Cordis US CORP. | 29 | $4,756 |
| Philips North America LLC | 26 | $3,010 |
| Siemens Medical Solutions USA, Inc. | 2 | $2,009 |
| Boston Scientific | 36 | $1,263 |
| Abbott | 26 | $823 |
| Nevro Corp. | 6 | $769 |
| Bard Peripheral Vascular, Inc. | 18 | $378 |
| Cardiovascular Systems Inc. | 14 | $327 |
| Johnson & Johnson | 13 | $241 |
| Medtronic | 2 | $211 |
| Resmed Corp | 5 | $145 |
| Cardinal Health 200 LLC | 8 | $130 |
| Vasorum USA Inc. | 1 | $115 |
| Penumbra, Inc. | 1 | $107 |
| Cook Medical LLC | 3 | $69 |
| Cagent Vascular Inc | 1 | $68 |
| Novartis | 4 | $57 |
| W. L. Gore & Associates, Inc. | 1 | $41 |
| Atricure, Inc. | 1 | $31 |
| Organogenesis Inc. | 1 | $27 |
| Veryan Medical Incorporated | 1 | $26 |
| Novo Nordisk | 1 | $24 |
| Biotronik Inc. | 1 | $19 |
| Merck | 1 | $16 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaCure 1470 Pro$12,213
- Navicross$11,025
- SABER$4,300
- Auryon Laser System 100-120 Vac$2,209
- GLIDESHEATH SLENDER$2,150
- ANGIO-SEAL$2,150
- CVX-300$750
- Lasers$731
- Senza$603
- (9520) IGT Devices Undivided$400
- CONCERTOTM$195
- (P84) IGT Devices Systems$142
- ENROUTE Transcarotid Neuroprotection System$117
- CELT ACD$115
- TheraSphere Y90 Glass Microspheres 10 GBq$114
- Supera peripheral stent system$111
- ELUVIA$107
- Indigo System$107
- IV Other$107
- (6578) Visions 018$104
How this compares
$43,072 in reported general payments places this provider in the 90th percentile of 111 vascular & interventional radiology providers in New Jersey.
See all vascular & interventional radiology providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 107 | $69,303 |
| ClopidogrelClopidogrel Bisulfate | 162 | $2,072 |
| Colchicine | 21 | $977 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 23 | $113 |
| Rosuvastatin Calcium | 16 | $104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $241 | $69,303107 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 vascular & interventional radiology providers in New Jersey.
Other vascular & interventional radiology in New Brunswick
- Michael DayanNew Brunswick$18K
- John RundbackTeaneck$507K
- Nicholas PetruzziGalloway$407K
- Sabina AminCamden$346K
- Israel SchurClifton$247K
- Micah WattsGalloway$225K
- Kevin HermanTeaneck$154K
- Elsie KohWoodland Park$150K
- Daniel BurrittVineland$112K
- Vincent GalloTeaneck$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.